Fatty Liver and Reflux: Causes and UK Treatments

Fatty liver and reflux are two increasingly common conditions that frequently occur together, often sharing the same underlying risk factors rather than one directly causing the other. Metabolic-associated steatotic liver disease (MASLD) and gastro-oesophageal reflux disease (GORD) are both strongly linked to obesity, insulin resistance, and a high-calorie diet. Understanding how these conditions interact, what symptoms to watch for, and which lifestyle changes can help both at once is essential for anyone managing either diagnosis. This article outlines the evidence, red-flag symptoms, and treatment options available in the UK.

Can fatty liver disease cause acid reflux symptoms?

Fatty liver does not directly cause acid reflux, but both conditions share risk factors such as obesity and insulin resistance, and excess visceral fat raises intra-abdominal pressure, increasing the likelihood of reflux symptoms.

Fatty liver disease and acid reflux frequently occur together, and there is growing evidence that the two conditions share common underlying causes rather than one directly causing the other. Metabolic-associated steatotic liver disease (MASLD, previously called non-alcoholic fatty liver disease or NAFLD) and gastro-oesophageal reflux disease (GORD) are both strongly linked to obesity, insulin resistance, and a high-calorie diet, which means many people develop both conditions simultaneously.

The liver itself does not produce acid reflux symptoms directly. However, excess abdominal fat increases intra-abdominal pressure, which can weaken the lower oesophageal sphincter and allow stomach acid to travel upward into the oesophagus.^[1][2] This mechanical effect means that people with significant hepatic steatosis, who often carry excess visceral fat, are at higher risk of experiencing reflux symptoms such as heartburn, regurgitation, and a sour taste in the mouth.

There is also emerging evidence that the gut microbiome plays a role in both conditions. Dysbiosis (an imbalance in gut bacteria) has been associated in observational studies with increased intestinal permeability, low-grade systemic inflammation, and altered bile acid metabolism, all of which may contribute to both liver fat accumulation and oesophageal irritation.^[4][5] This remains an active area of research and a direct causal pathway has not been established. While there is no confirmed direct causal link from fatty liver to reflux, the overlap in risk factors means that addressing one condition often benefits the other.

It is worth noting that some medicines used to manage liver-related metabolic conditions, such as certain lipid-lowering agents, can occasionally cause gastrointestinal side effects including dyspepsia. If you notice new or worsening digestive symptoms after starting any medicine, discuss this with a healthcare professional or pharmacist.

What symptoms should prompt you to see a GP?

See a GP promptly if you experience persistent heartburn more than twice a week, dysphagia, jaundice, unintentional weight loss, or signs of gastrointestinal bleeding, as these may indicate complications requiring investigation.

You should see your GP if you experience persistent heartburn occurring more than twice a week, difficulty swallowing, unexplained weight loss, or vomiting, as these symptoms may indicate complications of GORD or an underlying condition requiring investigation. Most people with fatty liver disease have no symptoms at all in the early stages, which is why it is often detected incidentally during blood tests or an ultrasound scan arranged for another reason.

Symptoms that warrant prompt GP review include:

• Persistent upper abdominal discomfort or pain, particularly in the right upper quadrant, which can occasionally be associated with liver enlargement

• Unexplained fatigue that does not improve with rest

• Jaundice (yellowing of the skin or whites of the eyes), dark urine, or pale stools, which may suggest more advanced liver disease

• Heartburn or regurgitation that does not respond to over-the-counter antacids after two weeks of regular use

• Difficulty or pain when swallowing (dysphagia), which should be assessed urgently; in line with NICE guidance on suspected cancer (NG12), dysphagia and certain combinations of upper gastrointestinal symptoms with age or weight loss warrant urgent referral to rule out oesophageal or gastric cancer^[6]

• Unintentional weight loss or loss of appetite

• Signs of gastrointestinal bleeding, such as vomiting blood, black or tarry stools (melaena), or unexplained iron-deficiency anaemia, which require urgent assessment

If you develop sudden, severe chest pain, contact 999 immediately, as this requires emergency assessment to rule out a cardiac cause before attributing it to reflux. For urgent advice that does not require an emergency response, NHS 111 is available around the clock.

People with known risk factors for fatty liver disease, including type 2 diabetes, obesity, or metabolic syndrome, should ensure they attend routine health checks. NICE guidance (NG49) recommends that GPs use the FIB-4 score to assess the risk of liver fibrosis in people with MASLD; the appropriate threshold varies with age, and a GP can advise on what your result means and whether further tests such as enhanced liver fibrosis (ELF) testing or elastography are needed.^[7] It is important to note that normal liver blood tests do not exclude significant fibrosis.^[7][8]

Lifestyle changes that can improve both conditions at once

Weight loss of 5 to 10 per cent of body weight, a Mediterranean-style diet, regular physical activity, and reducing alcohol and smoking can improve both MASLD and GORD simultaneously.

Weight loss of 5 to 10 per cent of body weight is one of the most effective interventions for both MASLD and GORD. NICE guidance (NG49) highlights sustained weight reduction as the cornerstone of MASLD management, noting that a loss of at least 5 per cent of body weight can reduce liver fat, while losses of around 10 per cent or more may lead to resolution of liver inflammation (MASH) in some people. Even modest weight loss reduces visceral fat, lowers intra-abdominal pressure, and can improve liver enzyme levels and reduce reflux frequency simultaneously.

Dietary changes are central to managing both conditions. A Mediterranean-style diet, rich in vegetables, wholegrains, legumes, oily fish, and olive oil, has the strongest evidence base for reducing liver fat and improving metabolic markers.^[11][12] For reflux specifically, it is helpful to:

• Eat smaller, more frequent meals rather than large portions, which reduce gastric distension

• Identify and avoid personal trigger foods: common triggers include fatty or fried foods, chocolate, caffeine, alcohol, and spicy dishes, though individual responses vary and not everyone is affected by the same foods

• Leave at least three hours between the evening meal and lying down

• Elevate the head of the bed by 15 to 20 centimetres if night-time symptoms are troublesome; using bed risers or a wedge under the mattress is more effective than extra pillows, which can increase pressure on the abdomen

Regular physical activity improves insulin sensitivity, reduces hepatic steatosis, and supports healthy weight maintenance. Both aerobic exercise (such as brisk walking or cycling) and resistance training have demonstrated benefit for liver health. The UK Chief Medical Officers' Physical Activity Guidelines recommend at least 150 minutes of moderate-intensity activity per week for adults, and this target is also reflected in NHS guidance.^[14][15]

Reducing alcohol intake is particularly important. Even in MASLD, which is not primarily alcohol-driven, alcohol can worsen liver inflammation and is a recognised trigger for reflux. The UK Chief Medical Officers' low-risk drinking guidelines advise keeping alcohol consumption to no more than 14 units per week, spread across three or more days, with several alcohol-free days each week.^[16] Smoking cessation is also beneficial, as smoking relaxes the lower oesophageal sphincter and contributes to systemic inflammation.

What treatments are available, and when is specialist care needed?

GORD is treated with alginates or PPIs per NICE CG184, while MASLD management focuses on metabolic risk factors; specialist referral is needed if fibrosis is suspected, PPI therapy fails, or urgent cancer criteria are met.

Treatment for fatty liver disease and acid reflux is largely guided by the severity of each condition, and most people with mild to moderate disease are managed effectively in primary care with lifestyle modification and, where appropriate, medication.

For GORD, NICE guidance (CG184) recommends a stepwise approach. Alginates (such as Gaviscon) can provide symptomatic relief for mild or intermittent symptoms. Proton pump inhibitors (PPIs) such as omeprazole or lansoprazole are the most commonly prescribed medicines for more frequent or troublesome reflux. They work by reducing acid production in the stomach and are typically trialled for four to eight weeks at standard dose. Where dyspepsia is the predominant symptom, testing and treating for Helicobacter pylori infection is also recommended before or alongside PPI therapy. PPIs are generally well tolerated, though long-term use has been associated with a small risk of low magnesium levels (hypomagnesaemia), vitamin B12 deficiency, and an increased susceptibility to certain gastrointestinal infections; the MHRA has issued Drug Safety Update guidance on these risks.^[19][20] Ongoing need for PPIs should be reviewed regularly with a GP, with step-down to the lowest effective dose where possible.

For MASLD, there is currently no medicine specifically licensed by the MHRA for the treatment of liver fat in the UK, though several agents are under active investigation and the regulatory landscape is evolving.^[21][22] Management therefore focuses on treating underlying metabolic risk factors. GLP-1 receptor agonists, which are MHRA-authorised for type 2 diabetes and, in some formulations, for chronic weight management, have shown promising effects on hepatic steatosis and fibrosis in clinical studies; however, they do not currently hold a UK licence for MASLD specifically, and their use is guided by their authorised indications.^[23][24] Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, where clinically appropriate options may be considered following assessment.

Referral to a hepatologist or gastroenterologist is appropriate when:

• Liver fibrosis is suspected, based on elevated liver enzymes, a raised FIB-4 score (interpreted using age-specific thresholds per NICE NG49), or abnormal liver stiffness on elastography; where the FIB-4 result is indeterminate, further assessment with ELF testing or elastography may be arranged

• GORD symptoms persist despite an adequate trial of PPI therapy (typically four to eight weeks), or if Barrett's oesophagus is suspected, in line with NICE CG184

• Cirrhosis or portal hypertension is identified

• Urgent cancer referral criteria are met, such as dysphagia or age 55 or over with weight loss alongside upper abdominal pain, reflux, or dyspepsia, per NICE NG12

Suspected side effects from any medicine can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Scientific References

1. Gastro-oesophageal reflux disease in obesity (Barak N et al.).
2. Disruption of the gastroesophageal junction by central obesity and waist belt: role of raised intra-abdominal pressure.
3. Pathophysiology of gastroesophageal reflux disease: how an antireflux procedure works (or does not work).
4. The Link Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Gastroesophageal Reflux Disease (Cureus).
5. Nonalcoholic fatty liver disease increases the risk of gastroesophageal reflux disease: A systematic review and meta-analysis.
6. Suspected cancer: recognition and referral (NG12).
7. Metabolic dysfunction-associated steatotic liver disease (NG49).
8. Diagnostic utility of noninvasive tests for significant liver fibrosis in patients with MASLD (Polish Archives of Internal Medicine).
9. Metabolic-dysfunction associated steatotic liver disease: clinical features and noninvasive methods of detection in young adults with obesity (European Journal of Gastroenterology & Hepatology).
10. The use of simple tests to predict biopsy-proven steatohepatitis in people with type 2 diabetes (European Journal of Gastroenterology & Hepatology).
11. Mediterranean diet and metabolic outcomes in NAFLD/MASLD: A systematic review and meta-analysis of randomized controlled trials (Clinical Nutrition ESPEN).
12. The impact of dietary interventions on liver health biomarkers in individuals with MASLD: a systematic literature review and meta-analysis of randomized controlled trials (European Journal of Nutrition).
13. Effects of Mediterranean diet, exercise, and their combination on body composition and liver outcomes in MASLD: a systematic review and meta-analysis of randomized controlled trials (BMC Medicine).
14. UK Chief Medical Officers' Physical Activity Guidelines – GOV.UK.
15. Physical activity guidelines for adults aged 19 to 64 – NHS.
16. Alcohol consumption: advice on low risk drinking – GOV.UK (UK Chief Medical Officers).
17. Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management (CG184).
18. Gastro-oesophageal reflux disease and dyspepsia in adults: CG184 – Chapter 1 Recommendations.
19. Proton pump inhibitors in long-term use: reports of hypomagnesaemia – MHRA Drug Safety Update.
20. Lansoprazole – BNF/NICE (MHRA PPI safety advice referenced).
21. Resmetirom (Rezdiffra) authorised to treat metabolic dysfunction-associated steatohepatitis (MASH) in adults.
22. Final scope – MASLD/MASH technology appraisal (GID-TA11414).
23. Semaglutide (Wegovy) approved to treat form of liver disease.
24. Semaglutide for treating moderate to advanced liver fibrosis caused by MASH – NICE in development (GID-TA11477).
25. Efficacy of GLP-1-based Therapies on MASLD and MASH: A Systematic Review and Meta-analysis (Journal of Clinical Endocrinology and Metabolism).
26. Effects of exercise intervention on glucose and lipid metabolism in patients with T2DM complicated by NAFLD: a three-level meta-analysis (Frontiers in Nutrition).
27. The impact of long-term exercise on liver function, fatty liver progression, and related metabolic markers in NAFLD patients: a meta-analysis of randomized controlled trials (Frontiers in Nutrition).
28. Resistance training for metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis (Frontiers in Physiology).

Frequently Asked Questions